Thus, NASPGHAN recommends performing a liver biopsy in children with risk of NASH and/or advanced fibrosis, considering risk factors such as ALT > 80 U/L, splenomegaly, AST/ALT > 1, type 2 diabetes, and panhypopituitarism. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.